Genprex, Inc.
GNPX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595248
No open-market purchases or sales by Genprex, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $154.9K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Genprex, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Genprex, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Longnecker Brent M | Director | 0Indirect | Apr 15, 2026 | 2 |
| Berger Mark Stanley | Chief Medical Officer | 21,692 | Feb 27, 2026 | 2 |
| Confer Ryan M. | President, CEO and CFO | 36,331 | Feb 27, 2026 | 2 |
| Moreno Toscano Jose Antonio | Director | 9,157 | Dec 23, 2025 | 1 |
| Wilson William R Jr. | Director | 9,157 | Dec 23, 2025 | 1 |
| Varner John Rodney | Chairman, President and CEO | 26,352 | Feb 21, 2024 | 0 |
| Vaczy Catherine M | EVP GC Chief Strategy Officer | 265,000 | Apr 24, 2023 | 0 |
| Kumar Hermant | Chief Mfgr & Tech Officer | 200,000 | Feb 22, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 (view filing) | Apr 14 | 1 day | Longnecker Brent MDirector | SSale | −8 | $1.23 | −$9.84 | −0.1%9.16K after | |
| Apr 15, 2026 (view filing) | Apr 14 | 1 day | Longnecker Brent MDirector | SSale | −10 | $1.23 | −$12.3 | −100.0%0 after | |
| Apr 24, 2023 (view filing) | Apr 21 | 3 days | Varner John RodneyChairman, President and CEO | PPurchase | +19.0K | $1.06 | +$20.1K | +1,055.6%20.8K after | |
| Apr 24, 2023 (view filing) | Apr 21 | 3 days | Vaczy Catherine MEVP GC Chief Strategy Officer | PPurchase | +20.0K | $1.07 | +$21.4K | +8.2%265.0K after |